Neal D. Shore, MD, FACS | Authors


Darolutomide Controls Local Symptoms in nmCRPC

September 11, 2021

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

The Utility of ODM-201 in CRPC

February 13, 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).